Journal
ANTIVIRAL RESEARCH
Volume 207, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2022.105423
Keywords
Flavivirus; Nonstructural protein 4B; Antivirals; Drug discovery
Categories
Funding
- NIH [U19AI171413, U19AI142759, U01AI151801]
- Sealy & Smith Foundation
- Kleberg Foundation
- John S. Dunn Foundation
- Amon G. Carter Foundation
- Summerfield Robert Foundation
- Edith and Robert Zinn Foundation
Ask authors/readers for more resources
Infections with mosquito-borne flaviviruses are a significant threat to public health, but there are currently no approved antiviral drugs for their treatment. The non-structural protein NS4B has emerged as a target for drug discovery due to its multiple roles in the virus life cycle. This review summarizes the latest knowledge on the structure and function of flavivirus NS4B, as well as the progress on antiviral compounds that target NS4B.
Infections with mosquito-borne flaviviruses, such as Dengue virus, ZIKV virus, and West Nile virus, pose sig-nificant threats to public health. Flaviviruses cause up to 400 million infections each year, leading to many forms of diseases, including fatal hemorrhage, encephalitis, congenital abnormalities, and deaths. Currently, there are no clinically approved antiviral drugs for the treatment of flavivirus infections. The non-structural protein NS4B is an emerging target for drug discovery due to its multiple roles in the flaviviral life cycle. In this review, we summarize the latest knowledge on the structure and function of flavivirus NS4B, as well as the progress on antiviral compounds that target NS4B.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available